What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...

NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

Digestible, actionable responses free up clinicians to focus more on patient care and less time searching and reviewing literature “The things I am looking for when I'm interacting with tools like ...